Use of Pyridostigmine for Constipation in Diabetics
Information source: Mayo Clinic
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Constipation; Diabetes Mellitus; Colonic Transit; Gastric Emptying
Intervention: Pyridostigmine (Drug); Placebo (Drug)
Phase: Phase 1/Phase 2
Status: Completed
Sponsored by: Mayo Clinic Official(s) and/or principal investigator(s): Adil E. Bharucha, MBBS, MD, Principal Investigator, Affiliation: Mayo Clinic
Summary
Doctors at Mayo Clinic are doing this study to learn if pyridostigmine, a drug, affects the
speed at which food travels through the stomach, intestines and colon, and if pyridostigmine
improves constipation symptoms in patients with diabetes. Pyridostigmine has been approved
by the Food and Drug Administration (FDA) for routine clinical use, however, its use as
proposed in this study is considered investigational.
Clinical Details
Official title: Pyridostigmine in Diabetics With Constipation: Randomized, Placebo-controlled, Double-blind Trial
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Colonic Geometric Center at 24 Hours (GC24) Measured by ScintigraphyAscending Colon Emptying Half-time (AC t1/2) Measured in Hours
Secondary outcome: Gastric Emptying Half-time (GE t1/2)Colonic Filling at 6 Hours Colonic Geometric Center at 48 Hours (GC48) as Measured by Scintigraphy Stool Frequency Per Day Stool Form/Consistency Stool Ease of Passage Sense of Completely Emptying Bowels Stool Frequency Per Week Heart Rate Before and After Treatment QTc Interval Before and After Treatment
Detailed description:
Chronic constipation in diabetes mellitus is associated with colonic motor dysfunction and
is managed with laxatives. Cholinesterase inhibitors increase colonic motility. The study
evaluated the effects of a cholinesterase inhibitor (pyridostigmine vs. placebo) on
gastrointestinal and colonic transit and bowel function in diabetic patients with
constipation.
After a 9-day baseline period, patients with diabetes mellitus and chronic constipation
without defecatory disorder will be randomized to oral placebo or pyridostigmine, starting
with 60 mg three times a day, increasing by 60 mg every third day up to the maximum
tolerated dose of 120 mg three times a day; this dose will be maintained for 7 days.
Gastrointestinal and colonic transit (assessed by scintigraphy) and bowel function will be
evaluated at baseline and the final 3 and 7 days of treatment, respectively.
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Subjects with diabetes mellitus (Type I or type II), diagnosed by a physician.
- On medical treatment for diabetes (oral medication or injected insulin) for at least
one year
- Symptomatic constipation at least 25% of the time in the past year (Rome II criteria
for functional constipation)
- 18-70 years of age
- Colonoscopy negative for obstructive lesions, cancer, or inflammatory bowel disease
(IBS) within the last 8 years if 50 years of age or older
- Able to provide written informed consent before participating in trial
- Able to communicate adequately with the Investigator and to comply with the
requirements for the entire study
Exclusion Criteria:
- History of pelvic floor dysfunction (other functional GI disorders, eg IBS, non-ulcer
dyspepsia are acceptable); Specifically, patients will be excluded if they have at
least 2 of the following 3 criteria:
- History of digital evacuation of the rectum or pressure on the posterior aspect
of the vagina or perineum to facilitate defecation
- Examination findings suggestive of puborectalis spasm or anismus, on assessment
by an experienced gastroenterologist with expertise in this field; i. e. high
anal sphincter tone at rest, failure of perineal descent by >1cm on straining,
and tenderness or paradoxical contraction of the puborectalis on digital
examination
- Requirement of > 200g to expel a rectal balloon during voluntary straining
- Abdominal surgery other than appendectomy, cholecystectomy, hysterectomy, tubal
ligation, or inguinal hernia repair
- Suspected or known gastrointestinal or genitourinary obstruction
- Uncontrolled hypertension (defined as > 150/90 at rest)
- Known cardiac arrhythmia or ECG abnormalities, i. e. cardiac conduction disturbances
(2nd or 3rd degree atrioventricular (AV) block, prolonged corrected QT interval
(QTc)(> 460 msec) or bradycardia (< 45 beats/minute))
- Renal insufficiency with serum creatinine greater than 2 mg/dl based on a reading
from the previous 6 months
- Asthma or chronic obstructive pulmonary disease requiring systemic steroids in the
previous 3 years (inhaled steroids acceptable)
- Current use of narcotics, gut prokinetic drugs (eg metoclopramide, domperidone,
tegaserod, senekot), anticholinergic medication (eg. Hyoscyamine, belladonna),
antidiarrheals (Imodium, Lomotil), or laxatives other than fiber supplements,
docusate, or glycerin suppositories. Patients on any of these restricted medications
must cease use at least 48 hours before starting and for the duration of both study
phases. No rescue laxatives will be permitted within 7 days of transit testing
- Patients who have taken any investigational medications within the past 30 days
- Known intolerance or allergy to eggs
- Pregnant or breast-feeding females
Locations and Contacts
Mayo Clinic, Rochester, Minnesota 55905, United States
Additional Information
Mayo Clinic Clinical Trials
Starting date: May 2006
Last updated: November 2, 2012
|